No Data
ASCLETIS-B (01672.HK) canceled 1.658 million shares on February 13.
Gelonghui reported on February 13 that ASCLETIS-B (01672.HK) announced the cancellation of 1.658 million shares repurchased on February 13, 2025.
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Zhitoong Hong Kong Stock Investment Log | January 28th
Hong Kong Stock Investment Journal | January 28, 2025
ASCLETIS-B (01672.HK) spent 2.22 million Hong Kong dollars to repurchase 0.55 million shares on January 24.
On January 24, Gelonghui reported that ASCLETIS-B (01672.HK) announced the repurchase of 0.55 million shares at a cost of 2.22 million Hong Kong dollars.
ASCLETIS-B (01672) spent 2.0321 million Hong Kong dollars on January 23 to repurchase 0.5 million shares.
ASCLETIS-B (01672) announced that on January 23, 2025, the company invested 2.0321 million...
Gilead Sciences - B [01672] is currently reported at 4.4 Hong Kong dollars, with an increase of 11.68%.
As of 09:30, Gilead Sciences - B [01672] is reported at 4.4 HKD, up 0.46 HKD or 11.68% from yesterday's closing price of 3.94 HKD, with a transaction volume of 1.7515 million HKD. Today's highest price is 4.4 HKD, and the lowest price is 4.15 HKD. Based on yesterday's closing price, the 10-day average price is 3.40 HKD, and the 50-day average price is 2.40 HKD, with a current PE of -26.53 times, and a 14-day Relative Strength Index of 66.20.
